These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 33115689)

  • 21. High response rate but short-term effect of romiplostim in paediatric refractory chronic immune thrombocytopenia.
    Seidel MG; Urban C; Sipurzynski J; Beham-Schmid C; Lackner H; Benesch M
    Br J Haematol; 2014 May; 165(3):419-21. PubMed ID: 24484542
    [No Abstract]   [Full Text] [Related]  

  • 22. Use of romiplostim in a hemodialysis patient with primary immune thrombocytopenia.
    Al-Jafar H; Giagounidis A; El-Rashaid K; Al-Ali M; Hakim AA
    Ann Pharmacother; 2012 Nov; 46(11):e31. PubMed ID: 23115229
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice.
    Ptushkin VV; Vinogradova OY; Pankrashkina MM; Chernikov MV; Arshanskaya EG; Tkachenko NE
    Ter Arkh; 2018 Aug; 90(7):70-76. PubMed ID: 30701925
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Remissions after long-term use of romiplostim for immune thrombocytopenia.
    Marshall AL; Scarpone R; De Greef M; Bird R; Kuter DJ
    Haematologica; 2016 Dec; 101(12):e476-e478. PubMed ID: 27587382
    [No Abstract]   [Full Text] [Related]  

  • 25. Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program.
    Khellaf M; Michel M; Quittet P; Viallard JF; Alexis M; Roudot-Thoraval F; Cheze S; Durand JM; Lefrère F; Galicier L; Lambotte O; Panelatti G; Slama B; Damaj G; Sebahoun G; Gyan E; Delbrel X; Dhedin N; Royer B; Schleinitz N; Rossi JF; Mahévas M; Languille L; Bierling P; Godeau B
    Blood; 2011 Oct; 118(16):4338-45. PubMed ID: 21832276
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study.
    Tarantino MD; Bussel JB; Blanchette VS; Despotovic J; Bennett C; Raj A; Williams B; Beam D; Morales J; Rose MJ; Carpenter N; Nie K; Eisen M
    Lancet; 2016 Jul; 388(10039):45-54. PubMed ID: 27103127
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Platelet aggregation response in immune thrombocytopenia patients treated with romiplostim.
    Al-Samkari H; Van Cott EM; Kuter DJ
    Ann Hematol; 2019 Mar; 98(3):581-588. PubMed ID: 30446804
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of romiplostim in patients with eltrombopag-resistant or -intolerant immune thrombocytopenia.
    Tsukamoto S; Nakaseko C; Takeuchi M; Kumagai K; Komatsu T; Tanaka H; Hara S; Koizumi M; Imai H; Yokota A; Takeuchi M; Inokuchi K; Matsuura Y; Aotsuka N; Wakita H
    Br J Haematol; 2013 Oct; 163(2):286-9. PubMed ID: 23862773
    [No Abstract]   [Full Text] [Related]  

  • 29. Treatment of chronic immune thrombocytopenia in children with romiplostim.
    Chaturvedi S; McCrae KR
    Lancet; 2016 Jul; 388(10039):4-6. PubMed ID: 27103125
    [No Abstract]   [Full Text] [Related]  

  • 30. A large observational study of patients with primary immune thrombocytopenia receiving romiplostim in European clinical practice.
    Steurer M; Quittet P; Papadaki HA; Selleslag D; Viallard JF; Kaiafa G; Janssens A; Kozak T; Wadenvik H; Schoonen M; Belton L; Kreuzbauer G
    Eur J Haematol; 2017 Feb; 98(2):112-120. PubMed ID: 27557853
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of romiplostim for primary immune thrombocytopenia in children.
    Escudero Vilaplana V; Aragonés JH; Fernández-Llamazares CM; Bieler CB; Rodríguez SM; Sáez MS
    Pediatr Hematol Oncol; 2012 Mar; 29(2):197-205. PubMed ID: 22376020
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of the novel thrombopoietin receptor-agonist romiplostim, in combination with steroids and immunoglobulins for the increase of platelets prior to splenectomy, in refractory immune thrombocytopenia: a case report.
    Sivera P; Ruella M; Gueli A; Hu H; Wade M; Tarella C
    Blood Coagul Fibrinolysis; 2012 Jun; 23(4):331-4. PubMed ID: 22343685
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The burden of immune thrombocytopenia in adults: evaluation of the thrombopoietin receptor agonist romiplostim.
    Deuson R; Danese M; Mathias SD; Schoonen M; Fryzek J
    J Med Econ; 2012; 15(5):956-76. PubMed ID: 22533524
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of self-administration of romiplostim by patients with chronic immune thrombocytopenia compared with administration by a healthcare provider.
    Selleslag D; Bird R; Altomare I; Giagounidis A; Janssens A; Pabinger I; Pullarkat V; Wei H; Kreuzbauer G
    Eur J Haematol; 2015 Feb; 94(2):169-76. PubMed ID: 25039799
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Romiplostim for the treatment of glioblastoma-related paraneoplastic autoimmune thrombocytopenia refractory to conventional therapy.
    Rodríguez-Lobato LG; Martinez-Cibrian N; Fernández-Avilés F; Gaya A; Pineda-Losada E; Esteve J
    Ann Hematol; 2016 Mar; 95(4):665-6. PubMed ID: 26787417
    [No Abstract]   [Full Text] [Related]  

  • 36. Comment on: Use of thrombopoietin receptor agonist (romiplostim) in neonatal autoimmune thrombocytopenia due to maternal immune thrombocytopenia.
    Mahat U; Talati R; Kodish E
    Pediatr Blood Cancer; 2019 Jun; 66(6):e27706. PubMed ID: 30854752
    [No Abstract]   [Full Text] [Related]  

  • 37. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP).
    Mazza P; Minoia C; Melpignano A; Polimeno G; Cascavilla N; Di Renzo N; Specchia G
    Ann Hematol; 2016 Jan; 95(2):239-44. PubMed ID: 26596973
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New synergistic efficacy of combination of romiplostim and steroid in refractory immune thrombocytopenia patients.
    Yoon JS; Lee YJ; Baek DW; Park HY; Park BE; Moon JH; Sohn SK
    Korean J Intern Med; 2018 Mar; 33(2):435-437. PubMed ID: 26947025
    [No Abstract]   [Full Text] [Related]  

  • 39. Rescue therapy with romiplostim for refractory primary immune thrombocytopenia during pregnancy.
    Decroocq J; Marcellin L; Le Ray C; Willems L
    Obstet Gynecol; 2014 Aug; 124(2 Pt 2 Suppl 1):481-483. PubMed ID: 25004319
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Romiplostim for the management of pediatric immune thrombocytopenia: drug development and current practice.
    Neunert CE; Rose MJ
    Blood Adv; 2019 Jun; 3(12):1907-1915. PubMed ID: 31239245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.